|Hepatitis B & C in Asia|
|Business Reports - Market Report|
Hepatitis B & C in Asia - Tapping the opportunity of high prevalence rates in China, Taiwan, South Korea and Turkey
China, Taiwan, South Korea and Turkey represent highly endemic areas for viral Hepatitis. For this report, 180 high-prescribing physicians where surveyed in these countries, providing a breakdown of numbers of treated patients and the most frequently prescribed regimens.
While HBV vaccination and blood screening practices have reduced the prevalence of hepatitis B and C, the disease burden in East Asia still remains significantly higher than in the 7MM. Prevalence of HBV across China, South Korea and Turkey ranges from 4-8% but exceeds 10% in Taiwan. The prevalence of HCV across these countries ranges from 1-4%.
Zeffix and Baraclude, either alone or in combination with other antiviral agents, are the most frequently prescribed drugs to treat hepatitis B.
Treatment regimens for HCV across the four countries are more uniform due to the availability of only a few therapeutic options. In all four markets, Pegasys and ribavirin is the most frequently prescribed combination for first line therapy. Options for second line are limited if patients fail on current standard of care.
Newer news items
|< Prev||Next >|
The leader shows that style is no substitute for substance, that creating an impression is not more potent than acting from one's center.